We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Neuraltus Pharmaceuticals, Inc today announced findings from a confirmatory Phase 2 study of its investigational therapy, NP001, in ALS patients with elevated levels of systemic inflammation.